Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 3/20 | 0.63 |
| ▸ | ECE1 | P42892 | 7/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21641803 | 1.00 | KDM4E (0.68) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29384133 | 0.98 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL29377160 | 0.94 | ACE (0.62) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL31674592 | 0.94 | KDM4E (0.60) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL9596908 | 0.93 | ACE (0.72) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL11855463 | 0.93 | ACE (0.72) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL5583839 | 0.93 | ACE (0.72) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL5612810 | 0.93 | ACE (0.72) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL9596897 | 0.93 | ACE (0.72) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL3359705 | 0.93 | ACE (0.72) | KDM4EMEN1LMNAMPOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12097237-B2 | Small molecule Ras inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-24 | — | — | US | claimed |
| US-20070207957-A1 | Composition For Accelerating Alcohol Metabolism Or Relieving Fatigue By Gluconeogenesis | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-09-06 | — | — | US | claimed |
| EP-1757289-A1 | COMPOSITION FOR ACCELERATION OF ALCOHOL METABOLISM OR RECUPERATION FROM FATIGUE THROUGH GLUCONEOGENESIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-12492422-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250297300-A1 | DETECTION, STAGING, MONITORING AND TREATING A DISEASE OR A CONDITION | Sunbird Bio, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-20250270512-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2025-08-28 | — | — | US | disclosed |
| US-20250223627-A1 | FLUOROGENIC SUBSTRATES FOR AMINOPEPTIDASE DETECTION IN BIOFLUIDS | Sunbird Bio, Inc. | 2025-07-10 | — | — | US | disclosed |
| US-20250215476-A1 | EX VIVO PROTEASE ACTIVITY DETECTION FOR HEPATOCELLULAR CARCINOMA | Sunbird Bio, Inc. | 2025-07-03 | — | — | US | disclosed |
| WO-2025137586-A2 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING PHOSPHATE SOLUBILIZATION IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-114306389-A | Application of periplaneta americana extract in preparation of product for treating stroke recovery | 西南大学 | 2022-04-12 | — | — | CN | disclosed |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | disclosed |
| US-20200040308-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604503-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | Ajinomoto Co., Inc. (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-102477068-B | Amino acid derivative for preparing thrombus dissolving medicament, and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2013-07-24 | — | — | CN | disclosed |
| CN-102477068-A | Amino acid derivative for preparing thrombus dissolving medicament, and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-05-30 | — | — | CN | disclosed |
| US-20070207957-A1 | Composition For Accelerating Alcohol Metabolism Or Relieving Fatigue By Gluconeogenesis | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1757289-A1 | COMPOSITION FOR ACCELERATION OF ALCOHOL METABOLISM OR RECUPERATION FROM FATIGUE THROUGH GLUCONEOGENESIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097237-B2 | Small molecule Ras inhibitors | KRAS, HRAS, NRAS | KDM4E 3829/4885MEN1 1244/4885LMNA 3756/4885 |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | CTSB, CTSE, CTSV | KDM4E 3703/4885MEN1 2492/4885LMNA 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.